Thrombotic Hazard Markers: Thrombomodulin

Tanashyan M.M.; Roitman E.V.; Raskurazhev A.A.; Kuznetsova P.I.; Mazur A.S.

doi:https://doi.org/10.17116/flebo202519041296

Close metadata

Recommended articles:

Triglycerides-Glucose Index as an integral biomarker of insulin resistance and cardiovascular diseases. Russian Journal of Preventive Medicine. 2025;(5):124-129

Hemostasis disorders during neoadjuvant therapy in patients with breast cancer. P.A. Herzen Journal of Oncology. 2025;(3):39-44

Myokines — the cardiometabolic risk potential biomarkers. Russian Journal of Preventive Medicine. 2025;(7):119-126

Study of athrombogenic and thrombogenic factors of the endothelium in women with an unexpected poor and suboptimal ovarian response during the treatment of infertility by methods of assisted reproductive technology. Russian Journal of Human Reproduction. 2025;(4):56-63

Intraopertive use of local hemostatics in infected wounds. Pirogov Russian Journal of Surgery. 2025;(11):94-100

Endosonoscopic dopplerography in the treatment of ulcerative gastrointestinal bleeding. Endoscopic Surgery. 2025;(6):74-78

Relationship of circulating caspases-1 and -8, their ratio with coronary artery atherosclerosis. Russian Journal of Preventive Medicine. 2026;(1):40-46

Ibuprofen combined with low-molecular-weight heparin does not affect hemostasis system in patients undergoing colorectal cancer surgery. Russian Journal of Anesthesiology and Reanimatology. 2026;(1):52-56

MicroRNA deregulation as a method for assessing the effectiveness of brachytherapy for choroidal melanoma. Russian Annals of Ophthalmology. 2026;(1):21-26

Abstract:

Thrombomodulin (TM) is an active link in coagulation and hemostasis, demonstrating multimodal properties due to its unique structure. TM is expressed mainly on endothelial cells of most vessels, in gestational tissues (placenta and myometrium), in smooth muscle cells of the arteries, and in immune cells. Normally, the TM blood level in healthy individuals does not exceed 10 ng/mL, and usually increases (sometimes decreases) in various abnormal conditions. The role of TM is not limited to the activation of fibrinolysis; it also includes the regulation of inflammation and the immune response, as well as neuro- and angioprotection. The therapeutic potential of recombinant TMs in disseminated intravascular coagulation and preeclampsia is currently under active investigation. In addition, the diagnostic and prognostic value of TM as a blood biomarker across a wide range of diseases is well established. However, the diagnostic utility of TM is still limited by its relatively low specificity. Nevertheless, the experience of using TM in clinical practice indicates the potential for further study of this molecule. This review provides up-to-date information on the structure of TM, its functions, and its current use in medical practice. Also, potential prospects for further study as a marker of thrombosis risk are addressed.

Keywords:

thrombomodulin

biomarker

hemostasis

fibrinolysis

thrombin-thrombomodulin complex

thrombotic complications

Authors:

Tanashyan M.M.

Russian Center of Neurology and Neurosciences

ORCID: 0000-0002-5883-8119

Roitman E.V.

Research Center of Neurology;
Pirogov Russian National Research Medical University

SPIN RSCI: 2050-6727
Scopus AuthorID: 7004167632
ResearcherID: M-6541-2017
ORCID: 0000-0002-3015-9317

Raskurazhev A.A.

Research Center of Neurology

ORCID: 0000-0003-0522-767X

Kuznetsova P.I.

Research Center of Neurology

ORCID: 0000-0002-4626-6520

Mazur A.S.

Research Center of Neurology

ORCID: 0000-0001-8960-721X

Received:

14.05.2025

Accepted:

27.07.2025

Close metadata

References:

Giri H, Biswas I, Rezaie AR. Thrombomodulin: a multifunctional receptor modulating the endothelial quiescence. J Thromb Haemost. 2024;22(4):905-914. https://doi.org/10.1016/j.jtha.2024.01.006
Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem. 1982;257(2): 859-864.
Li YH, Kuo CH, Shi GY, Wu HL. The role of thrombomodulin lectin-like domain in inflammation. J Biomed Sci. 2012;19(1):34. https://doi.org/10.1186/1423-0127-19-34
Fuentes-Prior P, Iwanaga Y, Huber R, Pagila R, Rumennik G, Seto M, Morser J, Light DR, Bode W. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature. 2000;404(6777):518-525. https://doi.org/10.1038/35006683
Isermann B, Hendrickson SB, Zogg M, Wing M, Cummiskey M, Kisanuki YY, Yanagisawa M, Weiler H. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Investig. 2001;108(4):537-546. https://doi.org/10.1172/JCI13077
Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol. 2012;34(1):107-125. https://doi.org/10.1007/s00281-011-0282-8
Boron M, Hauzer-Martin T, Keil J, Sun XL. Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures. TH Open. 2022;6(3):e194-e212. https://doi.org/10.1055/a-1801-2055
Loghmani H, Conway EM. Exploring traditional and nontraditional roles for thrombomodulin. Blood. 2018;132(2):148-158. https://doi.org/10.1182/blood-2017-12-768994
Goncharov NV, Popova PI, Avdonin PP, Kudryavtsev IV, Serebryakova MK, Korf EA, Avdonin PV. Endothelial markers in health and disease. Biologicheskie membrany. 2020;37(1):3-21. (In Russ.). https://doi.org/10.31857/S0233475519040054
Stepanova TV, Ivanov AN, Tereshkina NE, Popyhova EB, Lagutina DD. Markers of endothelial dysfunction: pathogenetic role and diagnostic sugnificance. Klinicheskaja laboratornaja diagnostika. 2019;64(1):34-41. (In Russ.).
Watanabe-Kusunoki K, Nakazawa D, Ishizu A, Atsumi T. Thrombomodulin as a Physiological Modulator of Intravascular Injury. Front Immunol. 2020;11:575890. https://doi.org/10.3389/fimmu.2020.575890
Artymuk NV, Astahov AA, Belokrinitskaia TE, Bulanov AYu, Zabolotskikh IB, Kulikov AV, Matkovskiy AA, Ovezov AM, Protsenko DN, Ronenson AM, Riazanova OV, Sinkov SV, Filippov OS, Shifman EM. Intensive care for disseminated intravascular coagulation syndrome (dic-syndrome, coagulopathy) in obstetrics. Russian Journal of Anesthesiology and Reanimatology. 2019;(2):5-26. (In Russ.). https://doi.org/10.17116/anaesthesiology20190215
Lin S-M, Wang Y-M, Lin H-C, Lee K-Y, Huang C-D, Liu C-Y, Wang C-H, Kuo H-P. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit Care Med. 2008;36(3):683-689. https://doi.org/10.1097/CCM.0B013E31816537D8
Wada H, Kaneko T, Ohiwa MM, Tanigawa M, Hayashi T, Tamaki S, Minami N, Deguchi K, Suzuki K, Nakano T. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol. 1993;44(2):101-105. https://doi.org/10.1002/ajh.2830440206
Ito T, Thachil J, Asakura H, Levy JH, Iba T. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Crit Care. 2019;23(1):280. https://doi.org/10.1186/s13054-019-2552-0
Vincent J-L, Francois B, Zabolotskikh I, Daga MK, Lascarrou J-B, Kirov MY, Pettilä V, Wittebole X, Meziani F, Mercier E, Lobo SM, Barie PS, Crowther M, Esmon CT, Fareed J, Gando S, Gorelick KJ, Levi M, Mira J-P, Opal SM, Parrillo J, Russell JA, Saito H, Tsuruta K, Sakai T, Fineberg D; SCARLET Trial Group. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial. JAMA. 2019;321(20):1993-2002. https://doi.org/10.1001/jama.2019.5358
Hoppensteadt D, Tsuruta K, Cunanan J, Hirman J, Kaul I, Osawa Y, Fareed J. Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin. Clin Appl Thromb Hemost. 2014;20(2):129-135. https://doi.org/10.1177/1076029613492875
Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost. 2015;13(4):508-519. https://doi.org/10.1111/jth.12841
Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5(1):31-41. https://doi.org/10.1111/j.1538-7836.2006.02267.x
Ryabinkina YuV, Piradov MA, Tanashyan MM, Shabalina AA, Kostyreva MV. Venous thrombogenesis and functional state of the hemorheology and hemostasis system in stroke patients. Annaly klinicheskoj i jeksperimental’noj nevrologii. 2016;10(1):6-13. (In Russ.).
Lebedeva MN, Vitkovskaya IV, Ivanova EYu, Lukinov VL, Rerikh VV. Venous thromboembolism in complicated cervical spine injury. Hirurgija pozvonochnika. 2024;21(1):14-26. (In Russ.). https://doi.org/10.14531/ss2024.1.14-26
Zhou K, Zhang J, Zheng Z-R, Zhou Y-Z, Zhou X, Wang L-D, Suo B, Jiang X-F, Liu P-J, Wang D-H. Diagnostic and Prognostic Value of TAT, PIC, TM, and t-PAIC in Malignant Tumor Patients With Venous Thrombosis. Clin Appl Thromb Hemost. 2020;26:1076029620971041. https://doi.org/10.1177/1076029620971041
Cheng X, Sun B, Liu S, Li D, Yang X, Zhang Y. Identification of thrombomodulin as a dynamic monitoring biomarker for deep venous thrombosis evolution. Exp Ther Med. 2021;21(2):142. https://doi.org/10.3892/etm.2020.9574
Luo H, Qiao Y. Correlation analysis of Blood TM, TG and D-dimer with deep venous Thrombosis formation in patients after Total Hip Arthroplasty. Pak J Med Sci. 2023;39(2):539-543. https://doi.org/10.12669/pjms.39.2.6989
Yang Y, Cheng B-J, Lu S. Thrombomodulin regulates doxorubicin sensitivity through epithelial-mesenchymal transition in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2017;21(1):95-101.
Sugano H, Shirai Y, Sato S, Hamatani S, Hamura R, Taniai T, Horiuchi T, Gocho T, Eto K, Ikegami T. Thrombomodulin expression impacts the recurrence and long-term survival in pancreatic cancer. Ann Gastroenterol Surg. 2021;5(4):567-574. https://doi.org/10.1002/ags3.12447
Hanly AM, Hayanga A, Winter DC, Bouchier-Hayes DJ. Thrombomodulin: tumour biology and prognostic implications. Eur J Surg Oncol. 2005;31(3):217-220. https://doi.org/10.1016/j.ejso.2004.11.017
Tanashyan MM, Shabalina AA, Roitman EV, Vavilova TV, Kuznetsova PI. Thrombogenicity in patients with ischemic stroke and pre-existing polycythemia vera. Vestnik RGMU. 2020;(4):49-55. (In Russ.). https://doi.org/10.24075/vrgmu.2020.052
Shabalina AA, Tanashyan MM, Kuznetsova PI, Khamidova ZM, Roitman EV. Antiangiogenic effects of acetylsalicylic acid in patients with polycythemia vera. Tromboz, gemostaz i reologija. 2019;(3):45-52. (In Russ.). https://doi.org/10.25555/THR.2019.3.0889
Seregina OB, Babaeva TN, Pospelova TI. Role of endothelial dysfunction as a manifestation of systemic inflammatory response in the pathogenesis of aggressive and indolent variants of non-Hodgkin’s malignant lymphoma. Sibirskij nauchnyj medicinskij zhurnal. 2019;39(1):125-135. (In Russ.). https://doi.org/10.15372/SSMJ20190118
Orlov SV, Domashenko MA, Kostyreva MV, Shabalina AA, Ionova VG, Tanashyan MM. Hemorheology and hemostasis in patients suffering from ischemic cerebral stroke and metabolic syndrome. Klinicheskaja medicina. 2007;85(1):40-43. (In Russ.).
Tanashyan MM. Hemostasis, hemorheology and atrombogenic activity of the vascular wall in angioneurology. Annaly klinicheskoj i jeksperimental’noj nevrologii. 2007;1(2):29-33. (In Russ.).
Cole JW, Xu H, Ryan K, Jaworek T, Dueker N, McArdle P, et al. Genetics of the thrombomodulin-endothelial cell protein C receptor system and the risk of early-onset ischemic stroke. PLoS One. 2018;13(11):e0206554. https://doi.org/10.1371/journal.pone.0206554
Zaharia A-L, Tutunaru D, Oprea VD, Tănase CE, Croitoru A, Stan B, Voinescu DC, Ionescu A-M, Coadǎ CA, Lungu M. Thrombomodulin Serum Levels — A Predictable Biomarker for the Acute Onset of Ischemic Stroke. Curr Issues Mol Biol. 2024;46(1):677-688. https://doi.org/10.3390/cimb46010044
Han Y, Wu S, Hu Q, Xiao J-Q, Wei D-M, Liu L-L, Li Z-Z. Thrombomodulin and High-Sensitive C-Reactive Protein Levels in Blood Correlate with the Development of Cerebral Infarction Among Asians. Mol Neurobiol. 2016;53(4):2659-2667. https://doi.org/10.1007/s12035-015-9279-y
Zhu Z, Guo D, Jia Y, Kaixin Zhang K, Shi M, Peng Y, Yang P, Chen J, Zhang J, Wang A, Xu T, Zhang Y, He J. Plasma Thrombomodulin Levels and Ischemic Stroke: A Population-Based Prognostic Cohort Study. Neurology. 2022;99(9):e916-e924. https://doi.org/10.1212/WNL.0000000000200783
Xu X, Song Y, Cao W, Bai X, Wang X, Gao P, Chen J, Chen Y, Yang B, Wang Y, Chen F, Ma Q, Yu B. Alterations of Hemostatic Molecular Markers During Acute Large Vessel Occlusion Stroke. J Am Heart Assoc. 2024;13(3):e032651. https://doi.org/10.1161/JAHA.123.032651
Wenzel J, Spyropoulos D, Assmann JC, Khan MA, Stölting I, Lembrich B, Kreißig S, Ridder DA, Isermann B, Schwaninger M. Endogenous THBD (Thrombomodulin) Mediates Angiogenesis in the Ischemic Brain-Brief Report. Arterioscler Thromb Vasc Biol. 2020;40(12):2837-2844. https://doi.org/10.1161/ATVBAHA.120.315061
Yang Z, Wang L, Zhang W, Wang X, Zhou S. Plasma homocysteine involved in methylation and expression of thrombomodulin in cerebral infarction. Biochem Biophys Res Commun. 2016;473(4):1218-1222. https://doi.org/10.1016/j.bbrc.2016.04.042
Evdokimenko AN, Gulevskaya TS, Tanashyan MM, Evdokimenko AN, Gulevskaya TS, Tanashyan MM. Immunohistochemical and ultrasonic signs of the disturbance of athrombogenic properties of endothelium in atherosclerosis of carotid sinus. Annaly klinicheskoj i jeksperimental’noj nevrologii.2016;10(4):32-38. (In Russ.).
Evdokimenko AN. Ultrastructural changes of endothelium in unstable atherosclerotic plaques of carotid sinus. Mezhdunarodnyj zhurnal prikladnyh i fundamental’nyh issledovanij. 2015;11(5):639-647. (In Russ.).
Abdurakhmanov ZM, Umarov BYa, Abdurakhmanov MM. Novel biomarkers of endothelial dysfunction in cardiovascular diseases. Racional’naja farmakoterapija v kardiologii. 2021;17(4):612-618. (In Russ.). https://doi.org/10.20996/1819-6446-2021-08-08
Kozhanova TV, Neudakhin EV, Zhilina SS, Mescheryakova TI, Abramov AA, Lukash EN, Prityko AG. The genetic susceptibility to atherosclerosis. Arhiv vnutrennej mediciny. 2018;8(6):407-417. (In Russ.). https://doi.org/10.20514/2226-67042018-8-6-407-417
Liu G, Huang L, Lv X, Guan Y, Li L. Thrombomodulin as a potential diagnostic marker of acute myocardial infarction and correlation with immune infiltration: Comprehensive analysis based on multiple machine learning. Transpl Immunol. 2024;85:102070. https://doi.org/10.1016/j.trim.2024.102070
Li Y-H, Chen J-H, Tsai W-C, Chao T-H, Guo H-R, Tsai L-M, Wu H-L, Shi G-Y. Synergistic effect of thrombomodulin promoter -33G/A polymorphism and smoking on the onset of acute myocardial infarction. Thromb Haemost. 2002;87(1):86-91.
Doggen CJ, Kunz G, Rosendaal FR, Lane DA, Vos HL, Stubbs PJ, Cats VM, Ireland H. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men. Thromb Haemost. 1998;80(5):743-748.
Pletsch-Borba L, Grafetstätter M, Hüsing A, Maldonado SG, Kloss M, Groß M-L, Johnson T, Sookthai D, Bugert P, Kaaks R, Kühn T. Biomarkers of vascular injury in relation to myocardial infarction risk: A population-based study. Sci Rep. 2019;9(1):3004. https://doi.org/10.1038/s41598-018-38259-y
Frydland M, Ostrowski SR, Møller JE, Hadziselimovic E, Holmvang E, Ravn HB, Jensen LO, Pettersson AS, Kjaergaard J, Lindholm MG, Johansson PI, Hassager C. Plasma Concentration of Biomarkers Reflecting Endothelial Cell- and Glycocalyx Damage are Increased in Patients With Suspected ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock. Shock. 2018;50(5):538-544. https://doi.org/10.1097/SHK.0000000000001123
Zhong Z, Ilieva H, Hallagan L, Bell R, Singh I, Paquette N, Thiyagarajan M, Deane R, Fernandez JA, Lane S, Zlokovic AB, Liu T, Griffin JH, Chow N, Castellino FJ, Stojanovic K, Cleveland DW, Zlokovic BV. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest. 2009;119(11): 3437-3449. https://doi.org/10.1172/JCI38476
Niu X-Y, Xie X-X, Tuo H-Z, Lv C-P, Huang Y-R, Zhu J, Liang S-Y, Du X-Y, Yang C-G, Hou S-J, Sun X-Y, Li L-J, Cui F, Huang Q-X, Jia Y-B, Wang Y-J, Liu R-T. Thrombomodulin reduces α-synuclein generation and ameliorates neuropathology in a mouse model of Parkinson’s disease. Cell Death Discov. 2024;10(1):167. https://doi.org/10.1038/s41420-024-01939-y
Wolter J, Schild L, Bock F, Hellwig A, Gadi I, Al-Dabet MM, Ranjan S, Rönicke R, Nawroth PP, Petersen K-U, Mawrin C, Shahzad K, Isermann B. Thrombomodulin-dependent protein C activation is required for mitochondrial function and myelination in the central nervous system. J Thromb Haemost. 2016;14(11):2212-2226. https://doi.org/10.1111/jth.13494
Ziliotto N, Lamberti N, Manfredini F, Straudi S, Baroni M, Tisato V, Carantoni M, Secchiero P, Basaglia N, Marchetti G, Bernardi F. Functional recovery in multiple sclerosis patients undergoing rehabilitation programs is associated with plasma levels of hemostasis inhibitors. Mult Scler Relat Disord. 2020;44:102319. https://doi.org/10.1016/j.msard.2020.102319
Cudna A, Bronisz E, Jopowicz A, Kurkowska-Jastrzębska I. Changes in serum blood-brain barrier markers after bilateral tonic-clonic seizures. Seizure. 2023;106:129-137. https://doi.org/10.1016/j.seizure.2023.02.012
Pindon A, Berry M, Hantaï D. Thrombomodulin as a new marker of lesion-induced astrogliosis: involvement of thrombin through the G-protein-coupled protease-activated receptor-1. J Neurosci. 2000;20(7): 2543-2550. https://doi.org/10.1523/JNEUROSCI.20-07-02543.2000
Lopez-Ramirez MA, Pham A, Girard R, Wyseure T, Hale P, Yamashita A, Koskimäki J, Polster S, Saadat L, Romero IA, Esmon CT, Lagarrigue F, Awad IA, Mosnier LO, Ginsberg MH. Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice. Blood. 2019;133(3):193-204. https://doi.org/10.1182/blood-2018-06-856062
de Mello Loures CG, Duarte RCF, Silva MVF, Cicarini WB, de Souza LC, Caramelli P, Borges KBG, das Graças Carvalho M. Hemostatic Abnormalities in Dementia: A Systematic Review and Meta-Analysis. Semin Thromb Hemost. 2019;45(5):514-522. https://doi.org/10.1055/s-0039-1688444
Zimnitskaya OV, Mozheiko EYu, Petrova MM. Biomarkers of vascular cognitive impairment. Kardiovaskuljarnaja terapija i profilaktika. 2021;20(3): 2677. (In Russ.). https://doi.org/10.15829/1728-8800-2021-2677
Batyrova AS, Vasilyeva EM, Bakanov MI, Surkov AN. Changes of angiogenic factors and markers of endothelial dysfunction in children and adolescents of Wilson—Konovalov disease. Rossijskij medicinskij zhurnal. 2018;24(6): 295-298. (In Russ.). https://doi.org/10.18821/0869-2106-2018-24-6-295-298
Crews DC, Bello AK, Saadi G; for the World Kidney Day Steering Committee. Burden, access and disparities in kidney disease. Nefrologija. 2019; 23(2):9-17. (In Russ.). https://doi.org/10.24884/1561-6274-2019-23-2-9-17
Tsukanov VV, Vasyutin AV, Tonkikh YuL, Onuchina EV, Petrunko IL, Rzhavicheva OS, Gilyuk AV, Beloborodova EV, Bezzabotnova OG, Baron II, Platonova EA. The Burden of Hepatic Pathologies in the Modern World. Some Quality Parameters of Management of Patients with Liver Cirrhosis in the Siberian Federal District. Doktor.Ru. 2019;(3):6-10. (In Russ.). https://doi.org/10.31550/1727-2378-2019-158-3-6-10
Nguyen VT, Nguyen-Phan HN, Ton TN, Hoang BB. Value of Serum Thrombomodulin as a Marker and Predictor in Patients with Sepsis-Associated Acute Kidney Injury. Int J Gen Med. 2023;16:2933-2941. https://doi.org/10.2147/IJGM.S417410
Lin S-M, Chang C-H, Lin T-Y, Huang AC-C, Lin C-H, Chen Y-C, Chu P-H. Plasma thrombomodulin levels are associated with acute kidney injury in patients with acute heart failure. Ann Med. 2022;54(1):3169-3176. https://doi.org/10.1080/07853890.2022.2142660
Liu K-L, Lee K-T, Chang C-H, Chen Y-C, Lin S-M, Chu P-H. Elevated plasma thrombomodulin and angiopoietin-2 predict the development of acute kidney injury in patients with acute myocardial infarction. Crit Care. 2014;18(3):R100. https://doi.org/10.1186/cc13876
Wei X, Du X, Liu Y, Wu J, Zhang J. High plasma soluble thrombomodulin levels indicated poor prognosis of decompensated liver cirrhosis: a prospective cohort study. Eur J Gastroenterol Hepatol. 2022;34(11):1140-1146. https://doi.org/10.1097/MEG.0000000000002428
Zhou X, Luo J, Liang X, Li P, Ren K, Shi D, Xin J, Jiang J, Chen J, He L, Yang H, Ma S, Li B, Li J. Plasma thrombomodulin as a candidate biomarker for the diagnosis and prognosis of HBV-related acute-on-chronic liver failure. Infect Drug Resist. 2024;17:1185-1198. https://doi.org/10.2147/IDR.S437926
Momot AP, Molchanova IV, Batrak TA, Belozerov DE, Trukhina DA, Kudinova IYu, Maksimova NV, Fadeeva NI, Serdyuk GV, Romanov VV. Reference values of hemostatic system parameters in normal pregnancy and after delivery. Problemy reprodukcii. 2015;21(1):89-97. (In Russ.). https://doi.org/10.17116/repro20152189-97
Wienhard J, Bielska B, Munstedt K, Lang U, Zygmunt M. Increased endothelial thrombomodulin (TM) expression in pregnancies complicated by IUGR. J Perinat Med. 2002;30(4):322-328. https://doi.org/10.1515/JPM.2002.047
Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost. 2003;1(7): 1515-1524. https://doi.org/10.1046/j.1538-7836.2003.00306.x
de Moerloose P, Mermillod N, Amiral J, Reber G. Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1. Thromb Haemost. 1998;79(3):554-556.
Cao Y, Zhang Z, Xu J, Yuan W, Wang J, Huang X, Shen Y, Du J. The association of idiopathic recurrent pregnancy loss with polymorphisms in hemostasis-related genes. Gene. 2013;530(2):248-252. https://doi.org/10.1016/j.gene.2013.07.080
Franchi F, Biguzzi E, Cetin I, Facchetti F, Radaelli T, Bozzo M, Pardi G, Faioni EM. Mutations in the thrombomodulin and endothelial protein C receptor genes in women with late fetal loss. Br J Haematol. 2001;114(3):641-646. https://doi.org/10.1046/j.1365-2141.2001.02964.x
Dusse L, Godoi L, Kazmi RS, Alpoim P, Petterson J, Lwaleed BA, Carvalho M. Sources of thrombomodulin in pre-eclampsia: renal dysfunction or endothelial damage? Semin Thromb Hemost. 2011;37(2):153-157. https://doi.org/10.1055/s-0030-1270343
Dusse LM, Alpoim PN, Lwaleed BA, de Sousa LP, das Graças MC, Gomes KB. Is there a link between endothelial dysfunction, coagulation activation and nitric oxide synthesis in preeclampsia? Clin Chim Acta. 2013;415:226-229. https://doi.org/10.1016/j.cca.2012.10.006
Popova IG, Nazarov SB, Sitnikova OG, Kuzmenko GN, Klycheva MM, Kharlamova NV, Parejshvili VV. Blood markers of fibrinolysis system and vascular wall state in neonates born to mothers with preeclampsia. Tromboz, gemostaz i reologija. 2021;(1):56-61. (In Russ.).
Kohli S, Singh KK, Gupta A, Markmeyer P, Lochmann F, Gupta D, Rana R, Elwakiel A, Huebner H, Ruebner M, Isermann B. Placental thromboinflammation impairs embryonic survival by reducing placental thrombomodulin expression. Blood. 2021;137(7):977-982. https://doi.org/10.1182/blood.2020005225
Kobayashi T, Kajiki M, Nihashi K, Honda G. Surveillance of the safety and efficacy of recombinant human soluble thrombomodulin in patients with obstetrical disseminated intravascular coagulation. Thromb Res. 2017;159:109-115. https://doi.org/10.1016/j.thromres.2017.08.017
Bovt EA, Shakhidzhanov SS, Filippova AE, Ataullakhanov FI, Rumyantsev AG. The role of D-dimer and other coagulation parameters for diagnosing hemostatic disorders in patients with COVID-19. Tromboz, gemostaz i reologija. 2023;(3):63-70. (In Russ.). https://doi.org/10.25555/THR.2023.3.1070
Kuznik BI, Roitman EV, Tsybikov NN, Shapovalov KG, Smolyakov YuN. Pluripotent mechanisms for regulation of hemostasis and thrombogenesis in COVID-19. Tromboz, gemostaz i reologija. 2023;(2):67-89. (In Russ.). https://doi.org/10.25555/THR.2023.2.1062
Jin X, Duan Y, Bao T, Gu J, Chen Y, Li Y, Mao S, Chen Y, Xie W. The values of coagulation function in COVID-19 patients. PLoS One. 2020;15(10):e0241329. https://doi.org/10.1371/journal.pone.0241329
Orynbek AM, Tileubai AS. Biomarker monitoring in COVID-19 patients with pulmonary fibrosis. (Monitoring biomarkerov u bol’nyh s fibrozom legkih, perenesshih COVID-19). Nauchnyj aspekt. 2023;12(4):1406-1410.] (In Russ.).
Nekaeva ES, Bolshakova AE, Malysheva ES, Galova EA, Belikina DV, Fedotov VD, Lyubavina NA, Fomin IV. Studying markers of endothelial dysfunction and hemoreological disorders in patients with COVID-19. (Izuchenie markerov jendotelial’noj disfunkcii I gemoreologicheskih narushenij u pacientov s COVID-19). Sovremennye problemy nauki i obrazovanija. 2021;(6):123. (In Russ.). https://doi.org/10.17513/spno.31221
Khaertynov KhS, Anokhin VA, Khaliullina SV, Salakhova EA, Zhemkova OV, Valiakhmetova LKh, Shaykhutdinova NA, Malykhina LYu, Utyusheva TS. Markers of endothelial dysfunction in convalescents of COVID-19 coronavirus infection. Prakticheskaja medicina. 2024;22(1):58-63. (In Russ.). https://doi.org/10.32000/2072-1757-2024-1-58-63